Answers are grounded in this paper and cite their sources.
Aims Recent clinical trials have shown promising results with drugs targeting the hepatocyte growth factor receptor (c-Met) for advanced non-small cell lung cancers overexpressing c-Met. We assessed reflex testing of c-Met immunohistochemistry (IHC) at diagnosis for NSCLC in the real-world. Methods We retrospectively collected clinical, pathological and molecular data of cases diagnosed with NSCLC in our institution from January 2021 to June 2023. We performed c-Met IHC (SP44 clone) and scored the expression using a H-score and a three-tier classification. Results 391 cases with interpretable c-Met IHC staining were included. The median age at diagnosis was 70 years (range 25–89 years) including 234 males (male/female ratio 1:5). 58% of the samples came from surgical resections, 35% from biopsies and 8% from cytological procedures. 52% of cases were classified as c-Met-positive (H-score≥150) and 19% were classified as c-Met high (≥50%, 3+). 43% of the c-Met neg presented with lymph node and/or visceral metastases at diagnosis vs 55% for c-Met high (p=0.042). 23% of the adenocarcinomas showed c-Met high expression vs 3% for squamous cell carcinomas (p=0.004). 27% of the c-Met neg cases had a high PD-L1 expression vs 58% of c-Met high cases (p<0.001). MET ex14 skipping was present in 8% of the c-Met high cases. Conclusions Systematic c-Met testing in daily routine for NSCLC patients is feasible, highlighting a potential correlation with clinicopathological and molecular features.
No takes yet. Share an insight, caveat, or question.
Bontoux et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: